Our 50 genomic experts are based in France and the US and are dedicated to R&D, BioT, Production, and Supporting departments for cutting edge research.
| HOW WE DO IT
in France as per 2021
Sites: based in Paris (France) and Wayne, PA (USA)
50% of Ph.D
Optimized proprietary database
| OUR CONTRIBUTION
Ten years ago, when I founded PathoQuest, I predicted that NGS would be incorporated into the ICH guidelines and that a paradigm shift would occur in the testing of biologics. In the coming years, I am confident that the NGS will replace the entire panel of standard tests and be vastly adopted as an all-in-one test to guarantee the viral safety of biologics and innovative therapies.
Prof. Marc Eloit
Founder and scientific adviser PathoQuest & Institut Pasteur Paris
PathoQuest participates in various groups, associations, and consortia for the innovation anchoring of Next-Generation Sequencing (NGS) as a cornerstone technology to improve the biosafety of biologics.
Let’s Start Something New
Welcome to PathoQuest!